Pulse Biosciences, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Pulse Biosciences, Inc. (PLSE) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $15.80 million as of 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2022-03-31
- 2021-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $15.80M.
- 2020-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $9.60M.
- 2019-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $14.20M.
- 2018-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $17.10M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2021-12-31 | $15.80M 10-K · filed 2022-03-31 |
| 2020-12-31 | $9.60M 10-K · filed 2021-03-12 |
| 2019-12-31 | $14.20M 10-K · filed 2020-03-16 |
| 2018-12-31 | $17.10M 10-K · filed 2019-03-14 |
| 2017-12-31 | $22.10M 10-K · filed 2018-03-16 |
| 2016-12-31 | $2.40M 10-K · filed 2017-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |